at Nasdaq.com (Jan 23, 2015)
Off sharply on Tuesday after filing to sell 7M shares, Alnylam Pharmaceuticals (ALNY +14.7%) is more than recouping its losses after pricing its offering (increased to 7.5M shares) at $10.75. A high short interest (11.2% of float shorted as of Jan. 31) could be contributing to recent volatility.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Jan 12, 2015)
at Nasdaq.com (Dec 24, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs